Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases
暂无分享,去创建一个
A. Bartoloni | G. Emmi | F. Bartalesi | M. Spinicci | A. Barilaro | L. Dies | J. Mencarini | G. Vitiello | A. Cavallo
[1] W. Alexander,et al. European Association for the Study of the Liver , 1968 .
[2] A. Vaglio,et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.
[3] N. Terrin,et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta‐analysis , 2017, Hepatology.
[4] Thomas Berg,et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.
[5] H. Yen,et al. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. , 2017, Clinical and experimental rheumatology.
[6] P. Lampertico,et al. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc–positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study , 2016, The Journal of Rheumatology.
[7] J. Feld,et al. Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis , 2015, Journal of viral hepatitis.
[8] M. Barone,et al. Safety of long‐term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection , 2015, Hepatology.
[9] K. Reddy,et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. , 2015, Gastroenterology.
[10] M. García-Retortillo,et al. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. , 2014, Reumatologia clinica.
[11] D. Vassilopoulos,et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection , 2012, Annals of the rheumatic diseases.
[12] P. Boura,et al. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. , 2013, Hippokratia.
[13] E. Ghrenassia,et al. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. , 2012, Joint, bone, spine : revue du rhumatisme.
[14] T. Hsieh,et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy , 2011, Annals of the rheumatic diseases.
[15] M. Haubitz,et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] D. Keskin,et al. A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.
[17] T. Umemura,et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.